Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Shen

Showing results (11-20 of 63) with videos related to

Pageof 7
Sort By:
International Journal of Radiation Oncology, Biology, Physics|October 1, 2008
Retrospective analysis of artifacts in four-dimensional CT images of 50 abdominal and thoracic radiotherapy patientsTokihiro Yamamoto, Ulrich Langner, Billy W Loo, et al.
American Journal of Clinical Oncology|May 6, 2009
Treatment of esophageal cancer based on histology: a surveillance epidemiology and end results analysisDaniel T Chang, Christopher Chapman, John Shen, et al.
Targeted Oncology|February 12, 2016
The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical developmentJun Gong, Gauri Kelekar, James Shen, et al.
International Journal of Surgery Case Reports|July 21, 2024
Synchronous metastatic prostate cancer and male breast cancer while on testosterone replacement therapy: Case reportJustin J Cheng, John Shen, Yashila Suresh, et al.
Clinics in Geriatric Medicine|October 9, 2022
Polypharmacy in OncologyJustin J Cheng, Asal M Azizoddin, Michael J Maranzano, et al.
Scientific Reports|December 7, 2013
Electrical/optical dual-function redox potential transistorShunpu Li, Wensi Wang, Ju Xu, et al.
Organic Letters|September 17, 2015
Improved Carbohydrate Recognition in Water with an Electrostatically Enhanced β-Peptide BundleMichael S Melicher, Allison S Walker, John Shen, et al.
Therapeutic Advances in Medical Oncology|February 1, 2018
Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and managementJohn Shen, Jason Chang, Melody Mendenhall, et al.
World Journal of Urology|May 4, 2020
VEGF inhibition in urothelial cancer: the past, present and futureSanaz Ghafouri, Aaron Burkenroad, Morgan Pantuck, et al.
Immunotherapy|January 5, 2021
Acute interstitial nephritis and PR3-ANCA following reintroduction of pembrolizumab: a case reportMatthew Mulroy, Sanaz Ghafouri, Anthony Sisk, et al.
Pageof 7

Showing results (11-20 of 63) with videos related to

Sort By:
Pageof 7
International Journal of Radiation Oncology, Biology, Physics|October 1, 2008
Retrospective analysis of artifacts in four-dimensional CT images of 50 abdominal and thoracic radiotherapy patientsTokihiro Yamamoto, Ulrich Langner, Billy W Loo, et al.
American Journal of Clinical Oncology|May 6, 2009
Treatment of esophageal cancer based on histology: a surveillance epidemiology and end results analysisDaniel T Chang, Christopher Chapman, John Shen, et al.
Targeted Oncology|February 12, 2016
The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical developmentJun Gong, Gauri Kelekar, James Shen, et al.
International Journal of Surgery Case Reports|July 21, 2024
Synchronous metastatic prostate cancer and male breast cancer while on testosterone replacement therapy: Case reportJustin J Cheng, John Shen, Yashila Suresh, et al.
Clinics in Geriatric Medicine|October 9, 2022
Polypharmacy in OncologyJustin J Cheng, Asal M Azizoddin, Michael J Maranzano, et al.
Scientific Reports|December 7, 2013
Electrical/optical dual-function redox potential transistorShunpu Li, Wensi Wang, Ju Xu, et al.
Organic Letters|September 17, 2015
Improved Carbohydrate Recognition in Water with an Electrostatically Enhanced β-Peptide BundleMichael S Melicher, Allison S Walker, John Shen, et al.
Therapeutic Advances in Medical Oncology|February 1, 2018
Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and managementJohn Shen, Jason Chang, Melody Mendenhall, et al.
World Journal of Urology|May 4, 2020
VEGF inhibition in urothelial cancer: the past, present and futureSanaz Ghafouri, Aaron Burkenroad, Morgan Pantuck, et al.
Immunotherapy|January 5, 2021
Acute interstitial nephritis and PR3-ANCA following reintroduction of pembrolizumab: a case reportMatthew Mulroy, Sanaz Ghafouri, Anthony Sisk, et al.
Pageof 7